A multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of lenalidomide in the treatment of complex regional pain syndrome type 1.

Trial Profile

A multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of lenalidomide in the treatment of complex regional pain syndrome type 1.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2014

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Complex regional pain syndromes
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 27 Aug 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 21 Oct 2008 Planned end date changed from 1 Mar 2008 to 1 Apr 2008, as reported by ClinicalTrials.gov.
    • 21 Oct 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top